Lipid abnormalities in renal failure: Consequences for the progression of renal failure and cardiovascular risk;Anomalies lipidiques au cours de l'insuffisance rénale: Conséquences sur la progression de l'insuffisance rénale et le risque cardiovasculaire

Nephrologie

Volumn 21, Issue 7, 2000, Pages 339-341

  Moulin, B ^a  

^a Hopital de l'Antiquaille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLELITHIASIS; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG INDICATION; DYSLIPIDEMIA; HUMAN; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 0034519836     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Lipids and the kidney
2. Relationship between serum cholesterol and diabetic nephropathy
3. Apolipoprotein-β-containing lipoproteins and the progression of renal insufficiency
4. Hypercholesterolemia - A determinant of renal function loss and deaths in IDDM patients with nephropathy
5. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE inhibitors
6. Decreased albuminuria by pravastatin in hypercholesterolemic patients with diabetes mellitus
7. Cholesterol lowering therapy may retard the progression of dibetic nephropathy
8. Lovastatin in glomerulonephritis patients with hyperlipidemia and heavy proteinuria
9. Partial remission of nephrotic syndrome in patient on long-term simvastatin
10. Does LDL-apheresis in steroid resistant nephrotic syndrome affect prognosis?
11. The nephrotic syndrome and ischaemic heart disease
12. Cardiovascular disease and the nephrotic syndrome: The other side of the coin
13. The increased risk of coronary heart disease associated with nephrotic syndrome
14. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidemia of nephrotic syndrome
15. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria
16. The effects of lovastatin in hyperlipidemic patients with nephrotic syndrome
17. Lovastatin therapy in nephrotic hyperlipidemia : Effects on lipoprotein metabolism
18. A controlled trial of fish oil in IgA nephropathy